OTC leadership USP Zdrowie is a leading Polish OTC and medicine manufacturer with a strong portfolio of premier brands such as Apap, Ibuprom, Gripex, Verdin, Stoperan, and Xenna, presenting a broad revenue opportunity through cross-selling of established products.

Regional focus Primary focus on Poland with a corporate channel emphasizing brand and advertising content, suggesting Sales opportunities tailored to the Polish market and potential partnerships or licensing aligned with local regulatory and distribution channels.

Tech backbone A diverse tech stack including Salesforce, SAP, Azure DevOps, Dynamics, MuleSoft, Power Apps and Power Automate indicates readiness for digital transformation, CRM-driven sales enablement, and scalable integration with potential partners or distributors.

Financial scale Revenue in the range of 50 to 100 million USD and a sizeable workforce (approximately 501-1000 employees) signal solid market presence and capacity for larger distribution agreements, co-marketing, or contract manufacturing arrangements.

Growth signals Recent activity such as introducing the Highp package and a clearly defined corporate communications channel point to ongoing product and market expansion, offering opportunities for collaborative go-to-market initiatives and bundled OTC solutions.